Preprint / Version 1

The Use of Immunotherapies in Triple-Negative Breast Cancer


  • Aubrey O'Donnell Polygence



Triple-negative breast cancer, Immune checkpoint inhibitors, Immunotherapy


Affecting millions of individuals every year, breast cancer is one of the most prevalent cancer subtypes to impact women worldwide. Triple-negative breast cancer (TNBC), specifically, proves to be one of the most difficult breast cancers to treat. Currently, the use of immunotherapy in TNBC patients is limited primarily to immune checkpoint inhibitors (ICIs) due to a lack of safe and effective alternative options. However, not all patients of the TNBC population respond effectively to ICIs. Therefore, the need for more immunotherapy options is crucial to the survival of many TNBC patients. In this review, we will discuss common immunotherapy options for TNBC patients and their efficacy. We will additionally review the emerging methods of immunotherapy use in TNBC patients and their potential future impacts. 


Aneglats, L., Prat, A. (2023). Treatment of Advanced or Metastatic Triple-negative

Breast Cancer With Adoptive Therapy of PD1+ TILS (TILS001).

Identification No. NCT05451784.

Barber G. N. (2015). STING: infection, inflammation and cancer. Nature reviews.

Immunology, 15(12), 760–770.

Bernier, C., Soliman, A. M., Gravel, M., Dankner, M., Savage, P. B., Petrecca, K., Park,

M., Siegel, P. H., Shore, G. C., & Roulston, A. (2018). DZ-2384 has a superior

preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy.

Capasso, A., Lang, J., Pitts, T. M., Jordan, K. R., Lieu, C. H., Davis, S. L., Diamond, J.

R., Kopetz, S., Barbee, J., Peterson, J., Freed, B. M., Yacob, B. W., Bagby, S. M.,

Messersmith, W. A., Slansky, J. E., Pelanda, R., & Eckhardt, S. G. (2019).

Characterization of immune responses to anti-PD-1 mono and combination

immunotherapy in hematopoietic humanized mice implanted with tumor

xenografts. Journal for immunotherapy of cancer, 7(1), 37.

Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001). CTLA-4-mediated

inhibition in regulation of T cell responses: mechanisms and manipulation in

tumor immunotherapy. Annual review of immunology, 19, 565–594.

Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S. A., Yusof, M. M., Gallardo,

C., Lipatov, O., Barrios, C. H., Holgado, E., Iwata, H., Masuda, N., Otero, M. T.,

Gokmen, E., Loi, S., Guo, Z., Zhao, J., Aktan, G., Karantza, V., Schmid, P., ...

KEYNOTE-355 Investigators (2020). Pembrolizumab plus chemotherapy versus

placebo plus chemotherapy for previously untreated locally recurrent inoperable

or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised,

placebo-controlled, double-blind, phase 3 clinical trial. Lancet (London, England),

(10265), 1817–1828.

Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X. D., Mauceri, H.,

Beckett, M., Darga, T., Huang, X., Gajewski, T. F., Chen, Z. J., Fu, Y. X., &

Weichselbaum, R. R. (2014). STING-Dependent Cytosolic DNA Sensing

Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in

Immunogenic Tumors. Immunity, 41(5), 843–852.

ECOG Performance Status Scale. (n.d.). ECOG-ACRIN Cancer Research Group.


Godet, I., & Gilkes, D. M. (2017). BRCA1 and BRCA2 mutations and treatment

strategies for breast cancer. Integrative cancer science and therapeutics, 4(1),


Ho, A. Y., Barker, C. A., Arnold, B. B., Powell, S. N., Hu, Z. I., Gucalp, A.,

Lebron-Zapata, L., Wen, H. Y., Kallman, C., D'Agnolo, A., Zhang, Z., Flynn, J.,

Dunn, S. A., & McArthur, H. L. (2020). A phase 2 clinical trial assessing

the efficacy and safety of Pembrolizumab and radiotherapy in patients with

metastatic triple-negative breast cancer. Cancer, 126(4), 850–860.

Isakoff, S. J. (2023). Radiation, Immunotherapy and PARP Inhibitor in Triple Negative

Breast Cancer (NADiR). Identification No. NCT04837209.

Jungles, K. M., Holcomb, E. A., Pearson, A. N., Jungles, K. R., Bishop, C. R., Pierce, L.

J., Green, M. D., & Speers, C. W. (2022). Updates in combined approaches of

radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Frontiers in oncology, 12, 1022542.

Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su,

X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., Chawla, A., Curran, M.,

Hwu, P., Sharma, P., Litton, J. K., Molldrem, J. J., & Alatrash, G. (2014). PD-L1

expression in triple-negative breast cancer. Cancer immunology research, 2(4),


Nanda, R., Chow, L. Q., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L.,

Pathiraja, K., Aktan, G., Cheng, J. D., Karantza, V., & Buisseret, L. (2016).

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase

Ib KEYNOTE-012 Study. Journal of clinical oncology: official journal of the

American Society of Clinical Oncology, 34(21), 2460–2467.

Obidiro, O., Battogtokh, G., & Akala, E. O. (2023). Triple Negative Breast Cancer

Treatment Options and Limitations: Future Outlook. Pharmaceutics, 15(7), 1796.

Prakash, O., Hossain, F., Danos, D., Lassak, A., Scribner, R., & Miele, L. (2020). Racial

Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic

and Non-biologic Factors. Frontiers in public health, 8, 576964.

Sceneay, J., Goreczny, G. J., Wilson, K., Morrow, S., DeCristo, M. J., Ubellacker, J. M.,

Qin, Y., Laszewski, T., Stover, D. G., Barrera, V., Hutchinson, J. N., Freedman, R.

A., Mittendorf, E. A., & McAllister, S. S. (2019). Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. Cancer discovery, 9(9), 1208–1227.

Varma, R., Wright, M., Abraham, J., & Kruse, M. (2022). Immune checkpoint inhibition in

early-stage triple-negative breast cancer. Expert Review of Anticancer Therapy,

(11), 1225–1238.

Zhao, Y., Deng, J., Rao, S., Guo, S., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M.,

Li, X., Li, W., Gu, L., Sun, Y., Zhang, Z., Wen, Q., Xiao, Z., & Li, J. (2022). Tumor

Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions

and Challenges. Cancers, 14(17), 4160.